TB Diagnostics: Global Market Analysis and Potential
|
|
- Chester Dorsey
- 5 years ago
- Views:
Transcription
1 TB Diagnostics: Global Market Analysis and Potential Madhukar Pai, MD, PhD McGill University, Montreal, Canada September 2012
2 Market analyses are important and necessary To support new product development To convince industries and investors about the need for investments in new TB tools To develop target product profiles (TPPs) that can guide product development and scale-up To inform donor/funder decisions 2
3 Global TB burden: how many people are screened for TB ever year? According to the World Health Organization, in 2010, there were ~9 million incident cases of TB Since ~7 people with TB symptoms need to be screened to detect one TB case, this means over 60 million people get tested for active TB every year In addition, there is testing for latent TB infection and MDR-TB 3 Source: WHO
4 Only one global TB market analysis has been done to date By FIND & TDR Published in Source: FIND
5 Findings from this analysis showed Annually over US$ 1 billion is spent worldwide on TB diagnostics One third (US$ 326 million) of this money is spent out side of the established market economies (EME),where 73% of TB diagnostic testing takes place In EME: latent TB testing (PPD) dominates In non-emes: active TB dominates (smears and chest x-rays) 5 Source: FIND/TDR, 2006
6 Potential market for new TB tests (global) The potential markets for improved tests to detect active disease are large: 80 million for point-of-care test (per year) 50 million for smear replacement (per year) 20 million tests for culture replacement tests (per year) 6 Source: FIND/TDR, 2006
7 This global analysis needs to be updated to account for Major recent changes in the TB dx landscape and policies Development of several new diagnostics that are replacing or supplementing older tests Shift from PPD skin testing to IGRAs in high income countries Donor-driven roll-out of new tools, especially molecular tests, in high burden countries Greater willingness of high burden countries (especially BRICS) to invest in new technologies and invest more in TB control 7
8 The recently published UNITAID TB Dx landscape provides a good snapshot of this evolving landscape 8
9 Old tools are being replaced/supplemented by new technologies Tuberculin IGRAs Conventional microscopy LED/FM microscopy Solid cultures Liquid cultures Conventional, phenotypic DST Molecular DST (LPA) Conventional PCR Cartridge-based NAATs 9
10 The policy environment is vastly different now 10 Source: WHO 2011
11 In high-income countries, there is a growing shift from tuberculin skin testing to IGRAs, or TST + IGRA T-SPOT.TB [Oxford Immunotec, UK] QuantiFERON-TB Gold In Tube [Cellestis Ltd, Qiagen] 11 Denkinger C et al. Clin Micro Infect 2011
12 For the first time, a molecular TB test is being rolled out for active TB in high burden countries; while sputum smears continue to be used As of August 2012: $9.98 per cartridge for public sector in high burden countries 12
13 After GeneXpert, several fast-followers are rapidly emerging, aiming at decentralized deployment Source: Pai NP, Pai M. Discovery Med
14 This image cannot currently be displayed. Molecular diagnostics improve upon current tools, providing a bridge to true point-of-care Dx Past and current Current and near term future Long term future (10-15 years+?) Expected health impact 14 Microscopy Very affordable Poor sensitivity Culture More expensive Slow time to result GeneXpert Next generation molecular Dx Molecular diagnostics Highly sensitive and specific Rapid time to results Affordability and accessibility increasing over time True point-of-care Dx (based on biomarker TBD) High performance Very affordable Accessible even to patients not reached by current Dx Source: BMGF
15 Need for regional market analyses and focus on BRICS Efforts are ongoing to engage industries and donors in emerging economies (India and China, in particular) to develop affordable Dx that can be scaled-up for TB and HIV 15
16 TB Diagnostics in India: Market Analysis Revised - Version 2 Shekhar Menon, MBA [Indian Institute of Management, Bangalore] Minal Madhavankandi, MBA [Indian Institute of Management, Bangalore] Mansi Chitalia, MBA [Clinton Health Access Initiative, New Delhi] Madhukar Pai, MD, PhD* [McGill University, Montreal] Full analysis is available at:
17 TB diagnostics that are currently in use in India Public sector (RNTCP) Refers to the testing facilities under the Revised National Tuberculosis Control Programme (RNTCP), the government tuberculosis programme Active TB: Sputum smear microscopy (direct ZN staining) Chest x-rays Drug resistant TB: Line probe assays Solid culture and DST Liquid culture and DST Latent TB and pediatric TB: Tuberculin skin test Private (non-rntcp) Includes all testing facilities in the private sector, government hospitals, medical colleges Active TB: Sputum smear microscopy (direct ZN and auramine staining) Chest x-rays Serological TB tests (ELISA and rapid tests) PCR (in-house or commercial) QuantiFERON-TB Gold In Tube Drug resistant TB: Line probe assays Liquid culture and DST Latent TB: Tuberculin skin test QuantiFERON TB Gold In Tube 17
18 Estimation of number of patients with suspected pulmonary TB Estimation of total pulmonary TB suspects (per year) National TB programme (RNTCP) Pulmonary TB suspects 1 7,550,522 Contribution of RNTCP to total pulmonary suspects 40% Contribution of Non RNTCP (private sector) to total pulmonary suspects 60% Non RNTCP Estimated number of pulmonary TB suspects 11,325,783 Total pulmonary TB suspects 18,876,305 Assumptions based on discussions with key stakeholders* We assumed the split of patients tested for pulmonary TB (pulmonary TB suspects) in RNTCP: Non-RNTCP sector to be 40: 60 based on discussions with various stakeholders* The split was applied to the pulmonary TB suspects in the RNTCP sector to calculate the number of pulmonary TB suspects in the Non-RNTCP sector Source: 1. RNTCP report: TB India 2011; Note: *Key stakeholders include RNTCP, WHO, BMGF, CHAI, FIND, GHS, private laboratory service providers, diagnostics manufacturers 18
19 Estimated RNTCP (public sector) spend on TB diagnosis TB test Volume Price per test 1 ($) Market value ($) Comments Sputum smear 15,101, ,752,610 Assumes two smear conducted microscopy 2 per suspect as per RNTCP diagnostic algorithm Line Probe Assay 13, ,333 (LPA) 3 Liquid culture 3 6, ,000 Total 15,121,044 38,025,943 Based on RNTCP reporting and data from stakeholders, we noted the volumes of TB tests conducted by the RNTCP (public) sector Using the unit cost per test, we calculated the total patient spend on the various pulmonary TB tests 19 Source: 1. Discussions with RNTCP and labs 2.RNTCP report: TB India 2011; 3. Data from FIND and BD Note: Exchange rate: 1USD = 50 INR
20 Estimated Non-RNTCP (private sector) spend on TB diagnosis TB test Volume Price per test 1 ($) Market value ($) Serology Rapid Card tests (lateral flow assays) 3,397, ,988,675 Serology ELISA (assumed 2 antibodies tested per 2,265, ,181,879 suspect) Sputum smear microscopy 2,831, ,078,614 Culture 1,132, ,375,084 PCR (in-house and commercial) 1,132, ,507,662 QuantiFERON-TB Gold In Tube 226, ,325,783 Line Probe Assay (LPA) 2, ,258 Total tests 10,988, ,570,955 Unit cost per test was used to calculate the total patient spend on pulmonary TB diagnosis in the Non-RNTCP sector 20 Source: : 1. Discussions with large lab chains Note: Exchange rate: 1USD = 50 INR
21 Total patient spend on TB diagnosis in India: ~$220 m TB testing in Volume Market value ($) RNTCP 15,121,044 38,025,943 Non RNTCP 10,988, ,570,955 Common tests (X-rays and TST) 15,274,290 45,649,624 Total tests 41,384, ,246,522 India accounts for about 25% of the global TB burden 21
22 WHO has discouraged commercial TB serological tests and India has recently banned these tests There is a substantial market now for a test that can replace TB serology 22
23 acement and usage scenarios to estimate essable market value Scenario (if a new TB test 1 were to ) Volume Price per test 2 ($) ote: 1USD = 50 INR No specific Target Product Profile (TPP) for the new TB test was assumed while developing the different scenarios Assumes that the new TB test will be imported Market value ($) Replace serology (rapid + ELISA) (capture 33%) 1,868, ,728,844 Test always prescribed for all suspects (Ideal) 11,325, ,051,637 Test prescribed for 70% of suspects (High) 7,928, ,536,146 Test prescribed for 30% of suspects (Medium) 3,397, ,515,491 Test prescribed for 10% of suspects (Low) 1,132, ,505,164 Replace smear (capture 33%) 4,983, ,877,995 Replace smear (capture 100%) 15,101, ,751,501 Replace culture (capture 33%) 2, ,281 Replace culture (capture 100%) 6, ,335
24 existing TPPs that need to be refined and integrated arket analyses to get at addressable market size a POC F/TAG/STP)* TPP for a simple and affordable molecular test TPP for a high throughput molecular test for centralized
25 ally, in the immediate term, we need an affordable molecular that can be used in health centers with a peripheral lab cess to Care by Infrastructure Category* ion Access to no infrastructure Access to minimal infrastructure Access to moderate/advanced infrastructure rica 25% 47% 28% ia 13% 29% 58% Potential Coverage 28% - 58% Current - Diagnostic Tools Potential Coverage 75% - 87% Mid Term Goal - POC Platform with Moderate Impact Potential Coverage 87% - 93%
26 e longer term, we need a simple POC test that can eployed in the community and health posts
27 lusions ough the exact size of the TB Dx global market today is not known, definitely likely to be higher than $1 billion because of two major ds in the past few years: ncome countries uberculin IGRAs iddle income countries croscopy Molecular
28 lusions ever, since current versions of IGRAs and molecular tests are ensive and challenging to scale-up, there is an opportunity for panies to develop: More affordable IGRAs or next-generation assays for latent TB infection that are more predictive for future disease More affordable molecular tests or next-generation assays for active TB and MDR-TB Truly innovative, simple technologies for POC use in decentralized settings
29 ese companies are already making progress along e lines example: B-IGRAs by Beijing Wantai Haikou VTI Biological Institute B molecular assays by: Ustar Biotechnologies CapitalBio hese products need to be internationally validated for policy commendations and global uptake/adoption Regulatory approvals are required but not sufficient for policy and global scale-up
30 t evidence is needed for global policy? t are the challenges for global scale-up? 30 J Infect Dis 2012 Int J Tuberc Lung Dis 2012
31 k you! o financial/industry nflicts erve as a consultant to e Bill & Melinda Gates undation eceive grant support om the Bill & Melinda ates Foundation & rand Challenges Canada
Value chain in action: the story of TB serology in India
Value chain in action: the story of TB serology in India Madhukar Pai, MD, PhD Associate Professor, McGill University, Montreal madhukar.pai@mcgill.ca The story of Mohan... (some years ago) Mohan, 25 year
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 4: Improving Access to Affordable and Quality TB Tests in India Authors: Madhukar Pai, MD, PhD Author and Series Editor Tuberculosis Tuberculosis (TB) remains one
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationTarget product profiles for next generation TB diagnostics. Claudia Denkinger, MD PhD MSc Head of TB, FIND
Target product profiles for next generation TB diagnostics Claudia Denkinger, MD PhD MSc Head of TB, FIND 29 th October 2014 The Global TB Epidemic Undiagnosed TB Undiagnosed TB Facts: 9 million TB cases
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More informationHow best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationKaren R Steingart, MD, MPH Madhu Pai, MD, PhD David Dowdy, MD Berlin, 11 November 2010
Karen R Steingart, MD, MPH Madhu Pai, MD, PhD David Dowdy, MD Berlin, 11 November 2010 I serve as co-chair of the Evidence Synthesis subgroup of Stop TB Partnership s New Diagnostics Working Group I am
More informationAdvanced TB Diagnostic Research
Course on Advanced TB Diagnostic Research McGill University, Montreal Data to scale up: building the evidence base for new diagnostics Michael Kimerling, MD, MPH Michael.Kimerling@gatesfoundation.org July
More informationINTENSIFIED TB CASE FINDING
INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationDiagnosis of tuberculosis
Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear
More informationDiagnostics product development projects
Page 0 Diagnostics product development projects Smiljka de Lussigny Technical Officer, HIV UNITAID Copenhagen, 23 September 2013 Page 1 1 2 3 About UNITAID HIV diagnostics market UNITAID s current investment
More informationPOSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH
POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH Akos Somoskövi, M.D., Ph.D. and Giorgio Roscigno, M.D. ANNUAL GLI MEETING, 4 th OCTOBER 2010 MERIEUX FOUNDATION, ANNECY Integrated Laboratory Network
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Tuberculosis: What Every Madhukar Pai, MD, PhD Author and Series Editor Abstract India has the highest burden of tuberculosis
More informationCosts of Novel Tuberculosis Diagnostics Will Countries Be Able to Afford It?
SUPPLEMENT ARTICLE Costs of Novel Tuberculosis Diagnostics Will Countries Be Able to Afford It? Andrea Pantoja, 1 Sandra V. Kik, 2 and Claudia M. Denkinger 3 1 Independent consultant for FIND, Zürich,
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationNext Generation TB Diagnostics An Update from BMGF. Lee Pyne-Mercier
Next Generation TB Diagnostics An Update from BMGF Lee Pyne-Mercier November 2012 Presentation Outline Foundation Strategic Context Next Generation TB Diagnostics Program TB Diagnostics Forum November
More informationThe Global Burden of TB (2010)
Madhukar Pai, MD, PhD Associate Professor, McGill University, Montreal, Canada Honorary Professor, University of Cape Town Professor Extraordinary, Stellenbosch University, South Africa madhukar.pai@mcgill.ca
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationLatest developments in WHO estimates of TB disease burden
Latest developments in WHO estimates of TB disease burden WHO Global Task Force on TB Impact Measurement meeting Glion, 1-4 May 2018 Philippe Glaziou, Katherine Floyd 1 Contents Introduction 3 1. Recommendations
More informationProcurement update: StopTB Partnership - Global Drug Facility (GDF)
Procurement update: StopTB Partnership - Global Drug Facility (GDF) Magali BABALEY Strategic Procurement and Business Intelligence Manager Stop TB Partnership, Global Drug Facility (GDF) team joint UNICEF-UNFPA-WHO
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationXpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work
Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection Results of Group Work DOTS expansion and enhancement Objective This group deals with the majority
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More information: uptake and impact of Xpert MTB/RIF
Photo: Riccardo Venturi 21-215: uptake and impact of Xpert MTB/RIF Wayne van Gemert WHO Global TB Programme, Geneva Joint Partners Forum for Strengthening and Aligning TB Diagnosis and Treatment 27-3 April
More informationWHERE DO WE GO FROM HERE?
WHERE DO WE GO FROM HERE? WHAT WILL BE REQUIRED TO ACHIEVE ZERO DEATHS FROM TUBERCULOSIS? SALMAAN KESHAVJEE, MD, PHD, SCM HARVARD MEDICAL SCHOOL BRIGHAM AND WOMEN S HOSPITAL PARTNERS IN HEALTH INTERNATIONAL
More informationModelling Innovative Diagnostic Tools for Tuberculosis
Modelling Innovative Tools for Tuberculosis Ivor Langley Basra Doulla, MoH, Tanzania Hsien-Ho Lin, NTU, Taiwan Kerry Millington Bertie Squire HaCRIC11 - SEPTEMBER 2011 Modelling Innovative Tools for Tuberculosis
More informationInnovative Finance: the power of innovation to save lives
Innovative Finance: the power of innovation to save lives GAVI s mission is to save children s lives and protect people s health by increasing access to immunisation in poor countries. To that end, the
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationEvidence on IGRAs in Low & Middle Income Countries. Madhukar Pai, MD, PhD McGill University, Montreal
Evidence on IGRAs in Low & Middle Income Countries Madhukar Pai, MD, PhD McGill University, Montreal Madhukar.pai@mcgill.ca Disclosure No industry/financial conflicts I co-chair the Stop TB Partnership
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationThese recommendations will remain in effect until the national shortage of PPD solution has abated.
Maryland Recommendations Regarding the National Shortage of Purified Protein Derivative (PPD) Solution; Attachment to Health Officer Memorandum National Shortages of Tubersol and Aplisol for TB Skin Testing;
More informationUNITAID. Dr Philippe Duneton Deputy Executive Director Copenhagen September 2012
UNITAID Dr Philippe Duneton Deputy Executive Director Copenhagen September 2012 Challenges Achievements WHO Prequalification UNITAID support for prequalification of medicines Since 2007 UNITAID support
More informationThe innovation gaps and challenges for MDR-TB. Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board
The innovation gaps and challenges for the diagnostic and treatment of TB and MDR-TB Blessina Kumar TB/ HIV Activist Community Representative & Vice Chair STBP Coordinating Board Diagnosis Overview of
More informationCULTURE OR PCR WHAT IS
CULTURE OR PCR WHAT IS BEST FOR AFRICA? Peter R Mason BRTI TB IN AFRICA GLOBAL 9 MILLION NEW CASES/YR 1.5 MILLION TB DEATHS AFRICA 95% TB DEATHS IN LMIC 9/22 HIGH BURDEN COUNTRIES IN AFRICA STRONG LINK
More informationHIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR
HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR 2015 2020 Presented by Vincent Habiyambere (WHO), Biyi Adesina (Avenir Health) and Meghan Wareham (CHAI) on behalf
More informationIndia s Contribution in Rolling out Newer and Rapid Diagnostics towards PMDT Scale-up
India s Contribution in Rolling out Newer and Rapid Diagnostics towards PMDT Scale-up Balasangameshwara Vollepore, FIND (India) FIND and Partners Symposium 43 rd Union World Conference on Lung Health November
More informationOngoing Research on LTBI and Research priorities in India
Ongoing Research on LTBI and Research priorities in India Dr. C.Padmapriyadarsini, MD, MS ICMR-National Institute for Research in Tuberculosis Chennai, India Technical Consultation Meeting on Programmatic
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationUNITAID. AMDS Partners Meeting. UNITAID Strategy & 2013 Call for Letters of Intent. Brenda Waning. Page 1
Page 1 UNITAID AMDS Partners Meeting UNITAID 2013-2016 Strategy & 2013 Call for Letters of Intent Brenda Waning Geneva 7 May, 2013 UNITAID s Six Strategic Objectives SO1: Increase access to simple, point-of-care
More informationAN ACTIVIST S GUIDE TO. Tuberculosis Diagnostic Tools
AN ACTIVIST S GUIDE TO Tuberculosis Diagnostic Tools FEBRUARY 2017 This guide was written by Khairunisa Suleiman and edited by Erica Lessem. Thanks to Bryn Gay (Treatment Action Group) and Dr. Wayne van
More informationInnovation, Access and Use Department of Essential Medicines and Health Products WHO
MARKETS FOR QUALITY-ASSURED PRODUCTS Sarah Garner and Francisco Blanco Innovation, Access and Use Department of Essential Medicines and Health Products WHO 1 Objectives Indicate market needs for medicines
More information2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:
The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.
More informationCosting of the Sierra Leone National Strategic Plan for TB
Costing of the Sierra Leone National Strategic Plan for TB 2016-2020 Introduction The Government of Sierra Leone established the National Leprosy Control Programme in 1973 with support from the German
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationVirtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine
Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine 3rd sector OR and developing countries 27th March 2013, London School of Economics
More informationUNITAID investments to innovate and scale up access to HIV diagnostics
UNITAID investments to innovate and scale up access to HIV diagnostics WHO Annual meeting with Diagnostic Manufacturers and Stakeholders 10 March 2016 Smiljka de Lussigny (HIV Diagnostics Programme Manager,
More informationPresentation by Dr Philippe Douste-Blazy. Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development
Presentation by Dr Philippe Douste-Blazy Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development The Millennium Goals : Hope for Humanity 2000 UN Millennium Summit
More informationDiagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm
Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm Kathryn Schnippel 1, Gesine Meyer-Rath 1,2, Lawrence Long 1, Wendy Stevens 3,4, Ian Sanne 1,2, and Sydney Rosen
More informationMultidrug-Resistant TB
Multidrug-Resistant TB Diagnosis Treatment Linking Diagnosis and Treatment Charles L. Daley, M.D. National Jewish Health University of Colorado Denver Disclosures Chair, Data Monitoring Committee for delamanid
More informationXpert MTB/RIF assay validation experience --- impact and plan in China
Xpert MTB/RIF assay validation experience --- impact and plan in China Dr. Zhao Yanlin Chinese Center for Disease Control & Prevention Dr. Richard O Brien FIND April. 16, 2013 Progress Contribution for
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationChildhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine
Childhood Tuberculosis Some Basic Issues Jeffrey R. Starke, M.D. Baylor College of Medicine TUBERCULOSIS IS A SOCIAL DISEASE WITH MEDICAL IMPLICATIONS THE GREAT PARADOX OF TUBERCULOSIS A CAUTIONARY TALE
More informationNguyen Van Hung (NTP, Viet Nam)
Technical Consultation Meeting on the Programmatic Management of Latent Tuberculosis Infection 31 August-1 September 2017, Seoul, Republic Korea Adopting new LTBI diagnostics at country level: perspective
More informationTuberculosis Screening and IPT: Experience from India
Tuberculosis Screening and IPT: Experience from India Dr B.B.Rewari WHO National consultant Care, Support and Treatment National Programme Officer (ART) National AIDS Control Organization New Delhi-110001,
More informationLaboratory Diagnosis of Tuberculosis: State-of-the-art
World Clin Pulm Crit Care Med. 2014;3(1):66-78. Laboratory Diagnosis of Tuberculosis: State-of-the-art Madhukar Pai MD PhD Department of Epidemiology and Biostatistics, McGill International TB Center,
More informationRichard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012
Global l Applications of IGRAs Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012 Disclosure I have no personal financial conflicts of I have no personal
More informationGlobal Health Advocacy & Diplomacy
Global Health Advocacy & Diplomacy Madhukar Pai, MD, PhD CANADA RESEARCH CHAIR IN EPIDEMIOLOGY & GLOBAL HEALTH DIRECTOR, MCGILL GLOBAL HEALTH PROGRAMS https://www.youtube.com/watch?v=ze7pkrjrid4 Case study:
More informationThe power of innovation to save lives
Innovative Finance The power of innovation to save lives May 2013 The challenge Life or death for a young child too often depends on whether he is born in a country where vaccines are available or not.
More informationADVANCED TB DIAGNOSTICS
VENUE HOSTS ADVANCED TB DIAGNOSTICS MCGILL UNIVERSITY MONTREAL JUNE 19-23, 2017 COURSE DIRECTOR: Madhukar Pai MD, PhD DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 Mon June 19 Tues June 20 Wed June 21 Thurs June 22 Fri
More informationUpdate on IGRA Predictive Value
Update on IGRA Predictive Value Sandra Kik, PhD Molebogeng Rangaka, MD, PhD Madhukar Pai, MD, PhD McGill International TB Centre, McGill University University of Cape Town & London School of Hygiene and
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017
TB FIT Modelling 24th Annual PhilCAT Convention Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017 TB-FIT - Objectives 1. Develop a computer model of patient pathways for diagnosis
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
More informationMadhukar Pai, MD, PhD Jessica Minion, MD
Optimism bias, inflated accuracy estimates, and contradicted findings in TB diagnostic research Madhukar Pai, MD, PhD [madhukar.pai@mcgill.ca] Jessica Minion, MD McGill University, Montreal 1 Context There
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationICASA SATELLITE SYMPOSIUM Tuesday, 1 December 18:30 20:30 Prof. Soudre Room Rainbow Towers Conference Centre. Twitter Hash Tag: #EIDInnovation
Optimizing Testing and Treatment of HIV-Exposed Infants: Creating Sustainable Markets for Point-of-Care Technologies within National Diagnostic Networks ICASA SATELLITE SYMPOSIUM Tuesday, 1 December 18:30
More informationDetect TB. Accurately. Easily.
Detect TB. Accurately. Easily. Fast and robust test results with TB-LAMP Molecular DX Smear microscopy misses nearly every second positive TB case We need new tests to rapidly diagnose people with TB;
More informationReceipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen
Recommendation Promote rapid delivery of specimens to the laboratory Use fluorescent acid-fast staining and promptly transmit results by phone, FAX, or electronically Identify growth as acid-fast and use
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More information7.5 South-East Asian Region: summary of planned activities, impact and costs
PART II: GLOBAL AND REGIONAL SCENARIOS FOR TB CONTROL 26 215 7.5 South-East Asian Region: summary of planned activities, impact and costs Achievements DOTS expanded rapidly in the South-East Asian Region
More informationPerformance of RNTCP NTI Bulletin 2005,41/3&4,
Performance of RNTCP NTI Bulletin 2005,41/3&4, 118-122 A Cohort Analysis of Performance of RNTCP in MS Subramanya Rao*, KP Unnikrishnan**, MA Sharada BACKGROUND Tuberculosis (TB) is one of the most serious
More informationAMDS Partners and Stakeholders Meeting CHAI HIV Diagnostics Forecasting Overview th September, 2014
AMDS Partners and Stakeholders Meeting CHAI HIV Diagnostics Forecasting Overview 29-30 th September, 2014 Agenda Introduction Overview of Global Diagnostics Forecasting Overview of Country Forecasting
More informationOriginal citation: Szczepura, Ala and Osipenko, Leeza (2012) Detection & Identification of Infectious Agents (DIIA) Innovation Platform: Health Econometrics, Economic Analysis Report: Point of Care Tests
More informationMEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment
MEMORANDUM To: From: Local Board of Health John Bernardo, MD, Tuberculosis Medical Officer Jennifer Cochran, MPH, Division Director Division of Global Populations and Infectious Disease Prevention Bureau
More informationExperience with implementation of Xpert MTB/RIF in India. Dr K S Sachdeva Addl. DDG (TB), Government of India
Experience with implementation of Xpert MTB/RIF in India Dr K S Sachdeva Addl. DDG (TB), Government of India Background Two ongoing projects being implemented in India, under RNTCP by FIND Gene Xpert feasibility
More informationTB Vaccine Development Strategy Overview
TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationIntroduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24
Diagnosis of extrapulmonaryand paediatric tuberculosis AW Dreyer Centre for Tuberculosis NICD Introduction Part of the global efforts to control tuberculosis (TB) include improving case detection, especially
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationOnline Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2019, Vol. 5, Issue 2, 01-06 Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 5.008 COMPARATIVE STUDY BETWEEN GENEXPERT MTB/RIF ASSAY AND DIRECT SMEAR MICROSCOPY(DSM) FOR
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationRole of subclinical TB: Can we model prevention of TB in the subclinical stages?
Role of subclinical TB: Can we model prevention of TB in the subclinical stages? Paul K. Drain, MD, MPH Depts. of Global Health, Medicine, Epidemiology Tuberculosis Research & Training Center University
More informationWHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES
WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES Immunization and vaccine development in the last decade Since the Millennium Summit in 2000, immunization substantial international
More informationHealth for Humanity 2020 Goals 2
2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationRapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.
Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients. Item Type Thesis Authors Patel, Ravikumar Publisher The University of Arizona. Rights Copyright
More informationToward a healthier 2020
Toward a healthier 2020 How citizenship and sustainability can help more people live healthier lives Photo Credit: Peace Corps We re creating a new vision of health. A vision that expands the ways we ve
More informationPerspectives on Ensuring Access to Vaccines in Lower Income Countries
Perspectives on Ensuring Access to Vaccines in Lower Income Countries Greg Widmyer Deputy Director, Vaccine Delivery Foundation Merieux January 20, 2015 Bill & Melinda Gates Foundation BMGF GLOBAL PROGRAMS
More informationVision and strategies to Increase Access to Innovative HIV Diagnostic Technologies. Willy Urassa. AMD STAKE HOLDERS MEETING 7-8 May 2013
Vision and strategies to Increase Access to Innovative HIV Diagnostic Technologies Willy Urassa 1 Outline Definition Introduction Vision Broad strategies Progress so far Recent experience 2 Expansion of
More informationTPP for test that predicts progression to active TB
TPP for test that predicts progression to active TB Claudia Denkinger, MD PhD MSc Head of TB Programme at FIND 3 rd December 2015, Union Meeting Cape Town Target Product Profiles http://apps.who.int/iris/bitstream/10665/135617/1/who
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More information